[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356838-105":59,"doc-detail-356838-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","convergent-evolution-of-complex-structural-variants-drives-therapy-resistance-in-metastatic-prostate-cancer-research","Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer - Research","","Targeted therapy prolongs survival in metastatic castration-resistant prostate cancer (mCRPC), yet resistance eventually emerges and remains lethal. DNA copy gains that amplify the androgen receptor (AR) locus are central to this resistance, and prior work indicates extra-chromosomal DNA (ecDNA) can drive the amplification. Here, the study reconstructs complex structural variant (cSV) profiles in 193 mCRPC tumors using whole genome and transcriptome sequencing with matched Hi-C data for 77 tumors. EcDNA is found in over half of biopsies, linked to key genomic events and evolving under AR pathway inhibitor therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/convergent-evolution-of-complex-structural-variants-drives-therapy-resistance-in-metastatic-prostate-cancer-research/356838/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/convergent-evolution-of-complex-structural-variants-drives-therapy-resistance-in-metastatic-prostate-cancer-research/356838.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main hypothesis about therapy resistance in mCRPC?","Question",{"text":113,"@type":114},"The study hypothesizes that extra-chromosomal DNA (ecDNA) and other complex structural variants (cSVs) influence established drivers of therapy resistance in mCRPC and continue evolving over time.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the cSV landscape analyzed in this research?",{"text":118,"@type":114},"Researchers reconstructed cSV profiles from 193 mCRPC tumors using whole genome and transcriptome sequencing, with matched Hi-C data for 77 tumors.",{"name":120,"@type":111,"acceptedAnswer":121},"What relationships were observed between ecDNA and resistance-associated genomic features?",{"text":122,"@type":114},"EcDNA is detected in more than half of mCRPC biopsies and is associated with whole genome doubling, chromothripsis, and inactivating TP53 alterations, and it amplifies driver genes including AR and MYC.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356838,1790473566,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26,"preview_page_count":81,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Moreno‑Rodriguez et al. Genome Biology (2026) 27:177  \n[https://doi.org/10.1](https://doi.org/10.1) 186/s13059‑026‑04074‑2  \nGenome Biology  \nRESEARCH Open Access  \nConvergent evolution of complex structural   variants drives therapy resistance in metastatic prostate cancer  \nThaidy Moreno‑Rodriguez1, Meng Zhang2,3, Arian Lundberg2, Raunak Shrestha2, Martin Sjöström2, Anupama Pasam4,5, Joanna Chan4, Lisa Devereux5, Adam Foye6, Xiaolin Zhu6, Alana S. Weinstein2, Anna S. Trigos4,5, Alexander W. Wyatt7,8, Joshi J. Alumkal9, Eric J. Small6,10, Rahul Aggarwal6,10, Scott M. Dehm 11,12,13, Matthew L. Bootsma 14,15,16, Shuang G. Zhao 14,15,16, Mathieu Lupien 17,18,19, Felix Y. Feng 1,2,6,10^, Shahneen Sandhu4,5† and David A. Quigley 1,10,20*†  \n\n| ^Felix Y. Feng is deceased. |\n| --- |\n| †Shahneen Sandhu and David A. Quigley are authors jointly supervised the work. |\n| *Correspondence:\u003Cbr>[david.quigley@ucsf.edu](david.quigley@ucsf.edu) |\n\n1 Department of Urology, UCSF, San Francisco, CA, USA  \nFull list of author information is available at the end of the article  \nAbstract  \nBackground: Targeted therapy prolongs the lives of men with metastatic castration‑ resistant prostate cancer (mCRPC) but mCRPC is ultimately lethal. DNA copy gains that amplify the Androgen Receptor (AR) gene locus are a key driver of resistance to targeted therapy in mCRPC. Our group has recently shown that extra‑chromosomal DNA (ecDNA) frequently drives this amplification. We hypothesized that ecDNA and other complex structural variants (cSVs) also affect other established drivers of therapy resistance in mCRPC and continue to evolve over time. To test this hypothe‑ sis, we reconstructed cSV profiles in 193 mCRPC tumors using whole genome and tran‑ scriptome sequencing, with matched Hi‑C data for 77 tumors.  \nResults: We identify ecDNA in more than half of mCRPC biopsies and show it fre‑ quently amplifies driver genes such as AR and MYC and their non‑coding enhancers. The presence of ecDNA is significantly associated with whole genome doubling, chromothripsis, and inactivating TP53 alterations. Deep sequencing analysis of 53 rapid autopsy samples shows cSVs amplifying AR can arise independently within distinct tumors in a single patient. Phylogenetic analysis of tumor evolution implicates this cSVas an early event during metastatic spread. Additionally, a paired analysis of mCRPC samples as patients developed resistance to AR pathway inhibitor (ARPI) therapy dem‑ onstrates cSVs evolve in response to ARPI and can be detected in both tumor tissue and circulating tumor DNA.  \nConclusions: We conclude that cSVs, particularly ecDNA, are a pervasive contributor to intra‑patient heterogeneity in late‑stage mCRPC and a key driver of targeted therapy resistance.  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the mate‑ rial. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/.)[.](creativecommons.org/licenses/by/4.0/.)  \nBackground  \nOne in nine people born with a prostate will develop prostate cancer during their lifetime [1]. Localized prostate cancer is frequently well-controlled with surgery, radiation, or active surveillance. However, metastatic prostate canc","cbCaikq9uuV1Pt8W","https://ap.wps.com/l/cbCaikq9uuV1Pt8W","pdf",5410379,24,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Background\n## Prostate cancer, ADT, and mCRPC\n## ARPI resistance mechanisms and AR locus amplifications\n## Complex structural variants: ecDNA and BFB amplification","[{\"question\":\"What is the main hypothesis about therapy resistance in mCRPC?\",\"answer\":\"The study hypothesizes that extra-chromosomal DNA (ecDNA) and other complex structural variants (cSVs) influence established drivers of therapy resistance in mCRPC and continue evolving over time.\"},{\"question\":\"How was the cSV landscape analyzed in this research?\",\"answer\":\"Researchers reconstructed cSV profiles from 193 mCRPC tumors using whole genome and transcriptome sequencing, with matched Hi-C data for 77 tumors.\"},{\"question\":\"What relationships were observed between ecDNA and resistance-associated genomic features?\",\"answer\":\"EcDNA is detected in more than half of mCRPC biopsies and is associated with whole genome doubling, chromothripsis, and inactivating TP53 alterations, and it amplifies driver genes including AR and MYC.\"}]","Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer - Research | PDF",1790127565,[147,151,155],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/e0d65ffdc34f154de612ea9daa9394b5.webp",983,1306,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/6312cc329d20814ac806a99d7f70aae8.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/d6a848827b76ddfb94446e97797da19a.webp",981,1303]